These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1755 related articles for article (PubMed ID: 25542804)

  • 1. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
    Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
    Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IF7-Conjugated Nanoparticles Target Annexin 1 of Tumor Vasculature against P-gp Mediated Multidrug Resistance.
    Yu DH; Liu YR; Luan X; Liu HJ; Gao YG; Wu H; Fang C; Chen HZ
    Bioconjug Chem; 2015 Aug; 26(8):1702-12. PubMed ID: 26076081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective eradication of tumor vascular pericytes by peptide-conjugated nanoparticles for antiangiogenic therapy of melanoma lung metastasis.
    Guan YY; Luan X; Xu JR; Liu YR; Lu Q; Wang C; Liu HJ; Gao YG; Chen HZ; Fang C
    Biomaterials; 2014 Mar; 35(9):3060-70. PubMed ID: 24393268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoparticle-mediated drug delivery to tumor neovasculature to combat P-gp expressing multidrug resistant cancer.
    Bai F; Wang C; Lu Q; Zhao M; Ban FQ; Yu DH; Guan YY; Luan X; Liu YR; Chen HZ; Fang C
    Biomaterials; 2013 Aug; 34(26):6163-74. PubMed ID: 23706689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature.
    Yu DH; Lu Q; Xie J; Fang C; Chen HZ
    Biomaterials; 2010 Mar; 31(8):2278-92. PubMed ID: 20053444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PEG-PLA nanoparticles modified with APTEDB peptide for enhanced anti-angiogenic and anti-glioma therapy.
    Gu G; Hu Q; Feng X; Gao X; Menglin J; Kang T; Jiang D; Song Q; Chen H; Chen J
    Biomaterials; 2014 Sep; 35(28):8215-26. PubMed ID: 24974009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CGKRK-modified nanoparticles for dual-targeting drug delivery to tumor cells and angiogenic blood vessels.
    Hu Q; Gao X; Kang T; Feng X; Jiang D; Tu Y; Song Q; Yao L; Jiang X; Chen H; Chen J
    Biomaterials; 2013 Dec; 34(37):9496-508. PubMed ID: 24054848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of colorectal cancer subcutaneous xenograft and experimental lung metastasis using nanoparticle-mediated drug delivery to tumor neovasculature.
    Wang C; Zhao M; Liu YR; Luan X; Guan YY; Lu Q; Yu DH; Bai F; Chen HZ; Fang C
    Biomaterials; 2014 Jan; 35(4):1215-26. PubMed ID: 24231414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. iNGR-modified PEG-PLGA nanoparticles that recognize tumor vasculature and penetrate gliomas.
    Kang T; Gao X; Hu Q; Jiang D; Feng X; Zhang X; Song Q; Yao L; Huang M; Jiang X; Pang Z; Chen H; Chen J
    Biomaterials; 2014 May; 35(14):4319-32. PubMed ID: 24565520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of nanoparticulate delivery systems in metronomic chemotherapy.
    Yu DH; Ban FQ; Zhao M; Lu Q; Lovell JF; Bai F; Wang C; Guan YY; Luan X; Liu YR; Fang C; Chen HZ
    Biomaterials; 2013 May; 34(16):3925-3937. PubMed ID: 23465835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo.
    Li JL; Sainson RC; Oon CE; Turley H; Leek R; Sheldon H; Bridges E; Shi W; Snell C; Bowden ET; Wu H; Chowdhury PS; Russell AJ; Montgomery CP; Poulsom R; Harris AL
    Cancer Res; 2011 Sep; 71(18):6073-83. PubMed ID: 21803743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer.
    Kuhnert F; Chen G; Coetzee S; Thambi N; Hickey C; Shan J; Kovalenko P; Noguera-Troise I; Smith E; Fairhurst J; Andreev J; Kirshner JR; Papadopoulos N; Thurston G
    Cancer Res; 2015 Oct; 75(19):4086-96. PubMed ID: 26377940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Self-aggregated pegylated poly (trimethylene carbonate) nanoparticles decorated with c(RGDyK) peptide for targeted paclitaxel delivery to integrin-rich tumors.
    Jiang X; Sha X; Xin H; Chen L; Gao X; Wang X; Law K; Gu J; Chen Y; Jiang Y; Ren X; Ren Q; Fang X
    Biomaterials; 2011 Dec; 32(35):9457-69. PubMed ID: 21911250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-function synthetic peptide derived from BMP4 for highly efficient tumor targeting and antiangiogenesis.
    Choi SH; Lee JY; Suh JS; Park YS; Chung CP; Park YJ
    Int J Nanomedicine; 2016; 11():4643-4656. PubMed ID: 27695323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
    Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R
    Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects.
    Maffucci T; Piccolo E; Cumashi A; Iezzi M; Riley AM; Saiardi A; Godage HY; Rossi C; Broggini M; Iacobelli S; Potter BV; Innocenti P; Falasca M
    Cancer Res; 2005 Sep; 65(18):8339-49. PubMed ID: 16166311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MMGZ01, an anti-DLL4 monoclonal antibody, promotes nonfunctional vessels and inhibits breast tumor growth.
    Xu Z; Wang Z; Jia X; Wang L; Chen Z; Wang S; Wang M; Zhang J; Wu M
    Cancer Lett; 2016 Mar; 372(1):118-27. PubMed ID: 26739060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platycodin D inhibits tumor growth by antiangiogenic activity via blocking VEGFR2-mediated signaling pathway.
    Luan X; Gao YG; Guan YY; Xu JR; Lu Q; Zhao M; Liu YR; Liu HJ; Fang C; Chen HZ
    Toxicol Appl Pharmacol; 2014 Nov; 281(1):118-24. PubMed ID: 25250884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects.
    Gao W; Jin K; Lan H; Han N; Cao F; Teng L
    Hepatogastroenterology; 2012; 59(120):2543-7. PubMed ID: 22534543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 88.